Samuel B. Eckert Professor of Engineering,
Cornell University; President & CEO, Hesperos, Inc.
Michael L. Shuler is the Samuel B. Eckert Professor of Engineering in Biomedical Engineering and in the School of Chemical and Biomolecular Engineering at Cornell University and CEO of Hesperos. Shuler received both of his degrees in chemical engineering (BS, University of Notre Dame, 1969 and Ph.D., University of Minnesota, 1973) and has been a faculty member at Cornell University since January 1974. Shuler’s research is focused on biomolecular engineering and includes pioneering the development of “Body-on-a-Chip” or microphysiological system for testing pharmaceuticals and chemicals for toxicity, creation of production systems for useful compounds, such as paclitaxel from plant cell cultures, and constructions of computer models of cells relating physiological function to genomic structure. Shuler and F. Kangi have authored a popular textbook, “Bioprocess Engineering; Basic Concepts”. He has an honorary doctorate from the University of Notre Dame. He has received the Amgen Award in Biochemical Engineering, as well as the Professional Progress, Food, Pharmaceutical and Bioengineering Division Award, and the Warren K. Lewis Awards from the American Institute of Chemical Engineers. Also, he was the inaugural awardee for the J.E. Bailey Award from the Society for Biological Engineering. He received the Pritzker Award from Biomedical Engineering Society and the Marvin Johnson Award from the American Chemical Society. Shuler has been elected to membership in the National Academy of Engineering and the American Academy of Arts and Science and is a fellow of numerous other professional societies.
“Body-on-a-Chip”: A Microphysiological System for Drug Development
Thursday, 18 September 2014 at 09:00
Add to Calendar ▼2014-09-18 09:00:002014-09-18 10:00:00Europe/London“Body-on-a-Chip”: A Microphysiological System for Drug DevelopmentLab-on-a-Chip, Microfluidics and Microarray World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Development of a human-based in vitro system has the potential to reduce dependency on animal testing and to make better predictions of human response to drugs. Also, there is the likelihood that by reducing the dependency on animals the process could be accelerated. In particular, in the event of pandemics or terrorism, the ability to use a human surrogate to rapidly screen possible drugs or candidate drug mixtures should be invaluable. Our efforts to construct human surrogates uses a combination of cell cultures and microfabrication. These devices have been referred to as "Body-On-a-Chip" systems. These devices are designed to be physical replicas of a physiologically based pharmacokinetic (PBPK) model where cell cultures or tissue engineered constructs are used to replace the differential equations for each organ compartment in the PBPK. A microfluidic system is used where each compartment is interconnect as they might be in a PBPK model. By using cell cultures in place of the equation, interactions of the drug with each tissue and communication between each tissue can be replicated even if the mechanisms are unknown and unexpected and would not be captured in the equation by themselves. Construction of a "pumpless" system is described and how might serve as a basis for a larger system (> 10 compartments) will be discussed. Such "chips" should be relatively low cost to construct and have the potential for broad application in drug development. I will discuss some of the issues in the design, construction and use of such devices.
Add to Calendar ▼2014-09-18 00:00:002014-09-19 00:00:00Europe/LondonLab-on-a-Chip, Microfluidics and Microarray World CongressLab-on-a-Chip, Microfluidics and Microarray World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com